对于 CML，第二代 TKI 应始终作为初始治疗药物使用。
A second-generation TKI should always be used as initial therapy for CML.
机构信息
Department of Leukemia, MD Anderson Cancer Center, Houston, TX.
出版信息
Blood Adv. 2018 Dec 26;2(24):3653-3655. doi: 10.1182/bloodadvances.2018018655.
Abstract
This article has a companion Point by Hantel and Larson.
摘要
本文有 Hantel 和 Larson 的观点与之呼应。
相似文献
1
A second-generation TKI should always be used as initial therapy for CML.对于 CML，第二代 TKI 应始终作为初始治疗药物使用。
Blood Adv. 2018 Dec 26;2(24):3653-3655. doi: 10.1182/bloodadvances.2018018655.
2
Bosutinib more effective than imatinib in CML.博舒替尼在慢性粒细胞白血病中比伊马替尼更有效。
Lancet Oncol. 2017 Dec;18(12):e716. doi: 10.1016/S1470-2045(17)30840-9. Epub 2017 Nov 9.
3
Optimizing tolerability of TKI therapy in CML.优化慢性粒细胞白血病中酪氨酸激酶抑制剂治疗的耐受性
Blood. 2014 Feb 27;123(9):1284-5. doi: 10.1182/blood-2014-01-546705.
4
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?二代或三代酪氨酸激酶抑制剂用于一般人群慢性髓性白血病的一线治疗：是否有真正的获益？
Cancer Med. 2021 Oct;10(20):6959-6970. doi: 10.1002/cam4.4186. Epub 2021 Sep 22.
5
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。
J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.
6
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
7
Bosutinib in the treatment of chronic myelogenous leukemia.博舒替尼治疗慢性粒细胞白血病。
Clin Adv Hematol Oncol. 2012 Nov;10(11):736-7.
8
Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.博舒替尼：用于治疗费城染色体阳性慢性髓性白血病患者的综述。
BioDrugs. 2014 Feb;28(1):107-20. doi: 10.1007/s40259-013-0082-x.
9
[Chronic Myelogenous Leukemia].[慢性粒细胞白血病]
Dtsch Med Wochenschr. 2018 Sep;143(18):1304-1310. doi: 10.1055/s-0043-121023. Epub 2018 Sep 10.
10
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.TKI 剂量减少可有效维持慢性髓性白血病患者的主要分子缓解。
Br J Haematol. 2021 Apr;193(2):346-355. doi: 10.1111/bjh.17286. Epub 2020 Dec 24.
引用本文的文献
1
[Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].酪氨酸激酶抑制剂治疗初诊慢性髓性白血病的现状：一项国内多中心回顾性真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):215-224. doi: 10.3760/cma.j.cn121090-20231108-00255.
2
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.晚期慢性髓系白血病治疗的最新进展
Curr Hematol Malig Rep. 2023 Dec;18(6):234-242. doi: 10.1007/s11899-023-00709-4. Epub 2023 Aug 31.
3
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.异基因造血细胞移植在第三代酪氨酸激酶抑制剂时代的慢性期慢性髓性白血病患者中的应用：来自 EBMT 慢性恶性肿瘤工作组的回顾性研究。
Am J Hematol. 2023 Jan;98(1):112-121. doi: 10.1002/ajh.26764. Epub 2022 Oct 31.
4
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.美国老年慢性髓性白血病患者使用酪氨酸激酶抑制剂的当代实践模式。
Ther Adv Hematol. 2021 Nov 30;12:20406207211043404. doi: 10.1177/20406207211043404. eCollection 2021.
5
Therapeutic Challenges in Chronic Myeloid Leukemia: A Case-Based Discussion.慢性髓性白血病的治疗挑战：基于病例的讨论
J Med Cases. 2020 Jul;11(7):215-220. doi: 10.14740/jmc3510. Epub 2020 Jun 29.
6
Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.慢性粒细胞白血病一线治疗的长期生存、血管闭塞性事件及疗效生物标志物：一项荟萃分析
Cancers (Basel). 2020 May 15;12(5):1242. doi: 10.3390/cancers12051242.
7
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations.伴有BCR-ABL和NPM1突变的急性髓系白血病
Case Rep Hematol. 2019 Apr 11;2019:6707506. doi: 10.1155/2019/6707506. eCollection 2019.
本文引用的文献
1
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.博舒替尼对比伊马替尼用于新诊断的慢性髓性白血病：随机 BFORE 试验结果。
J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.
2
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.伊马替尼作为慢性粒细胞白血病一线治疗的评估：随机CML研究IV的10年生存结果及非CML决定因素的影响
Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.
3
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
4
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.DASISION的5年最终研究结果：达沙替尼与伊马替尼治疗初治慢性髓性白血病患者的试验
J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.
5
Moving treatment-free remission into mainstream clinical practice in CML.推动无治疗缓解进入 CML 的主流临床实践。
Blood. 2016 Jul 7;128(1):17-23. doi: 10.1182/blood-2016-01-694265. Epub 2016 Mar 24.
6
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.用博舒替尼治疗的费城染色体阳性白血病患者心脏和血管毒性的长期评估
Am J Hematol. 2016 Jun;91(6):606-16. doi: 10.1002/ajh.24360. Epub 2016 Apr 13.
7
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.伊马替尼治疗的慢性髓性白血病患者的继发性恶性肿瘤：CML研究IV的长期观察
Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. Epub 2016 Feb 9.
8
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.一线尼罗替尼与伊马替尼治疗慢性期慢性髓性白血病的长期获益与风险：随机ENESTnd试验的5年更新
Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.
9
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.酪氨酸激酶抑制剂时代慢性期慢性髓性白血病患者的相对生存率：来自六项前瞻性临床试验的患者数据分析
Lancet Haematol. 2015 May;2(5):e186-93. doi: 10.1016/S2352-3026(15)00048-4. Epub 2015 Apr 20.
10
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.伊马替尼400mg、伊马替尼800mg、达沙替尼和尼洛替尼用于慢性期慢性髓性白血病患者的长期分子和细胞遗传学反应及生存结果：来自五项临床试验患者数据的回顾性分析
Lancet Haematol. 2015 Mar;2(3):e118-28. doi: 10.1016/S2352-3026(15)00021-6. Epub 2015 Mar 20.
Zotero 插件